Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,635 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group study.
Oude Ophuis CM, Verhoef C, Rutkowski P, Powell BW, van der Hage JA, van Leeuwen PA, Voit CA, Testori A, Robert C, Hoekstra HJ, Grünhagen DJ, Eggermont AM, van Akkooi AC. Oude Ophuis CM, et al. Among authors: robert c. Eur J Surg Oncol. 2016 Dec;42(12):1906-1913. doi: 10.1016/j.ejso.2016.05.012. Epub 2016 May 27. Eur J Surg Oncol. 2016. PMID: 27266406
Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma.
Elliott B, Scolyer RA, Suciu S, Lebecque S, Rimoldi D, Gugerli O, Musat E, Sharma RN, Lienard D, Keilholz U, Testori A, Eggermont A, MacKie R, Robert C, Cook M, Thompson JF, Angevin E, Spatz A; European Organization for Research and Treatment of Cancer Melanoma Group. Elliott B, et al. Among authors: robert c. Clin Cancer Res. 2007 Jul 1;13(13):3825-30. doi: 10.1158/1078-0432.CCR-07-0358. Clin Cancer Res. 2007. PMID: 17606713
Small molecules and targeted therapies in distant metastatic disease.
Hersey P, Bastholt L, Chiarion-Sileni V, Cinat G, Dummer R, Eggermont AM, Espinosa E, Hauschild A, Quirt I, Robert C, Schadendorf D. Hersey P, et al. Among authors: robert c. Ann Oncol. 2009 Aug;20 Suppl 6(Suppl 6):vi35-40. doi: 10.1093/annonc/mdp254. Ann Oncol. 2009. PMID: 19617296 Free PMC article. Review.
Anti-CTLA-4 antibody adjuvant therapy in melanoma.
Eggermont AM, Testori A, Maio M, Robert C. Eggermont AM, et al. Among authors: robert c. Semin Oncol. 2010 Oct;37(5):455-9. doi: 10.1053/j.seminoncol.2010.09.009. Semin Oncol. 2010. PMID: 21074060 Review.
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria.
van der Ploeg AP, van Akkooi AC, Rutkowski P, Nowecki ZI, Michej W, Mitra A, Newton-Bishop JA, Cook M, van der Ploeg IM, Nieweg OE, van den Hout MF, van Leeuwen PA, Voit CA, Cataldo F, Testori A, Robert C, Hoekstra HJ, Verhoef C, Spatz A, Eggermont AM. van der Ploeg AP, et al. Among authors: robert c. J Clin Oncol. 2011 Jun 1;29(16):2206-14. doi: 10.1200/JCO.2010.31.6760. Epub 2011 Apr 25. J Clin Oncol. 2011. PMID: 21519012
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Robert C, et al. N Engl J Med. 2011 Jun 30;364(26):2517-26. doi: 10.1056/NEJMoa1104621. Epub 2011 Jun 5. N Engl J Med. 2011. PMID: 21639810 Free article. Clinical Trial.
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Salès F, Schadendorf D, Patel P, Dummer R, Robert C, Keilholz U, Yver A, Spatz A. Eggermont AM, et al. Among authors: robert c. Eur J Cancer. 2012 Jan;48(2):218-25. doi: 10.1016/j.ejca.2011.09.028. Epub 2011 Nov 5. Eur J Cancer. 2012. PMID: 22056637
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, Punt CJ, Salès F, Dummer R, Robert C, Schadendorf D, Patel PM, de Schaetzen G, Spatz A, Keilholz U. Eggermont AM, et al. Among authors: robert c. J Clin Oncol. 2012 Nov 1;30(31):3810-8. doi: 10.1200/JCO.2011.41.3799. Epub 2012 Sep 24. J Clin Oncol. 2012. PMID: 23008300 Clinical Trial.
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.
O'Day SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, Robert C, Schachter J, Testori A, Mackiewicz J, Friedlander P, Garbe C, Ugurel S, Collichio F, Guo W, Lufkin J, Bahcall S, Vukovic V, Hauschild A. O'Day SJ, et al. Among authors: robert c. J Clin Oncol. 2013 Mar 20;31(9):1211-8. doi: 10.1200/JCO.2012.44.5585. Epub 2013 Feb 11. J Clin Oncol. 2013. PMID: 23401447 Clinical Trial.
1,635 results